BTK Inhibitors Versus Venetoclax as First- or Second-Line Therapy in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Evidence Study. [PDF]
Roeker LE +4 more
europepmc +1 more source
Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88. [PDF]
Xu M +12 more
europepmc +1 more source
Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors. [PDF]
Nwankwo N, Reddy A, Kumar S, Zafar M.
europepmc +1 more source
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL. [PDF]
Gentile G +26 more
europepmc +1 more source
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist. [PDF]
Balıkçı E +19 more
europepmc +1 more source
QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors. [PDF]
Aloui M +10 more
europepmc +1 more source
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Treon SP, Sarosiek S, Castillo JJ.
europepmc +1 more source

